CAJ | 학술논문

伊马替尼是胃肠间质瘤（GIST）术后辅助治疗及晚期复发或转移性患者的一线治疗手段。对于局限性GIST，术前伊马替尼治疗能缩小肿瘤体积，提高R0切除率，保留器官功能；对于复发转移性 GIST ，虽然目前尚无充分的循证医学依据推荐进行伊马替尼联合残余灶切除手术，但经过多学科充分讨论评估后，在伊马替尼疗效最大化且未发生疾病进展前进行手术，无疑对减轻肿瘤负荷、减少继发耐药之可能以及延长患者生存时间十分有益。本文通过分析近年来的临床试验结果及相关“指南”，分析术前伊马替尼的治疗价值及手术时机的选择。
이마체니시위장간질류（GIST）술후보조치료급만기복발혹전이성환자적일선치료수단。대우국한성GIST，술전이마체니치료능축소종류체적，제고R0절제솔，보류기관공능；대우복발전이성 GIST ，수연목전상무충분적순증의학의거추천진행이마체니연합잔여조절제수술，단경과다학과충분토론평고후，재이마체니료효최대화차미발생질병진전전진행수술，무의대감경종류부하、감소계발내약지가능이급연장환자생존시간십분유익。본문통과분석근년래적림상시험결과급상관“지남”，분석술전이마체니적치료개치급수술시궤적선택。
Imatinib is the key medication for adjuvant therapy in gastrointestinal stromal tumors (GIST) and the first line therapy for patients with metastatic or recurrent GIST. Preoperative treatment with imatinib may improve R0 resection rate and provide the chance of metastasectomy for cytoreduction as well as prolonging patient′s survival. We investigate the significance of neoadjuvant therapy of imatinib and the timing of surgery by reviewing clinical trials and consensus in recent years.